STEMI 直接 PCI 后压力导丝与 CMR 评估的冠状动脉微血管功能障碍预测长期结局
本研究纳入 198 例接受直接 PCI 的 STEMI 患者,同期行 IMR 与 CMR 的 MVO 评估,按两者是否异常分为三组。中位随访 40.1 个月,主要终点发生 34 例(17%);长期来看,高 IMR 或 MVO 任一提示 CMD 者(Group 2)与两者均异常者(Group 3)的不良结局风险相似,均较无显著 CMD 者升高,主要由心力衰竭驱动。
要点
- STEMI 直接 PCI 后,IMR>40 U 或 CMR 示 MVO 任一存在即提示长期不良结局风险升高。
- 两者均异常者 1 年时风险显著升高(HR 12.6),但长期与仅一项异常者结局相似。
- 长期不良结局主要由心力衰竭驱动,报告 MVO 时应提示临床关注心衰风险。
核心结论
- 缺血后 CMD 使长期不良结局风险增加 4 倍以上,主要由心力衰竭的发生驱动。
- 以侵入性 IMR>40 U 或 CMR 评估的 MVO 任一指标定义 CMD,所显示的不良结局风险相似。
研究设计与样本
- 研究为单中心前瞻性队列,共纳入 198 例接受直接 PCI 的 STEMI 患者。
- 所有患者均行压力导丝 IMR 测定与 CMR 的 MVO 评估,并按两者结果分为三组。
- 主要终点为全因死亡、新诊断心力衰竭、心脏骤停、持续性室速/室颤及植入型心律转复除颤器植入的复合终点。
- 中位随访 40.1 个月。
关键影像表现/征象
- Group 3(IMR>40 U 且存在 MVO)占 23.7%,Group 2(IMR>40 U 或 MVO 任一)占 40.9%。
- 随访期间主要终点共发生 34 例(17%)。
诊断标准与关键数值
- CMD 分组标准:Group 1 为 IMR≤40 U 且无 MVO;Group 2 为 IMR>40 U 或 MVO;Group 3 为 IMR>40 U 且 MVO。
- 1 年随访时,Group 3 较 Group 1 结局更差(HR 12.6,95%CI 1.6–100.6,P=0.017),Group 2 未达统计学显著(HR 7.2,95%CI 0.9–57.9,P=0.062)。
- 长期随访中,Group 2(HR 4.2,95%CI 1.4–12.5,P=0.009)与 Group 3(HR 5.2,95%CI 1.7–16.2,P=0.004)不良结局风险相似。
临床应用与阅片要点
- STEMI 直接 PCI 后行 CMR 时,发现 MVO 应视为 CMD 的影像标志并提示长期心衰风险。
- IMR 与 CMR 的 MVO 任一异常即具有长期预后意义,报告时不宜仅以两者均异常才提示高危。
局限性
- 原文未报告研究局限性。
- 单中心设计与样本量 198 例可能限制结果的普适性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study sought to evaluate the long-term prognostic implications of coronary microvascular dysfunction (CMD) when assessed with both cardiovascular magnetic resonance (CMR) and index of microcirculatory resistance (IMR) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).
BACKGROUND: Post-ischemic CMD can be assessed using the pressure-wire based IMR and/or by the presence of microvascular obstruction (MVO) on CMR.
METHODS: A total of 198 patients with STEMI underwent IMR and MVO assessment. Patients were classified as follows: Group 1, no significant CMD (low IMR [≤40 U] and no MVO); Group 2, CMD with either high IMR (>40 U) or MVO; Group 3, CMD with both IMR >40 U and MVO. The primary endpoint was the composite of all-cause mortality, diagnosis of new heart failure, cardiac arrest, sustained ventricular tachycardia/fibrillation, and cardioverter defibrillator implantation.
RESULTS: CMD with both high IMR and MVO was present in 23.7% of the cases (Group 3) and CMD with either high IMR or MVO was observed in 40.9% of cases (Group 2). At a median follow-up of 40.1 months, the primary endpoint occurred in 34 (17%) cases. At 1 year of follow-up, Group 3 (hazard ratio [HR]: 12.6; 95% confidence interval [CI]: 1.6 to 100.6; p = 0.017) but not Group 2 (HR: 7.2; 95% CI: 0.9 to 57.9; p = 0.062) had worse clinical outcomes compared with those with no significant CMD in Group 1. However, in the long-term, patients in Group 2 (HR: 4.2; 95% CI: 1.4 to 12.5; p = 0.009) and those in Group 3 (HR: 5.2; 95% CI: 1.7 to 16.2; p = 0.004) showed similar adverse outcomes, mainly driven by the occurrence of heart failure.
CONCLUSIONS: Post-ischemic CMD predicts a more than 4-fold increase in long-term risk of adverse outcomes, mainly driven by the occurrence of heart failure. Defining CMD by either invasive IMR >40 U or by CMR-assessed MVO showed similar risk of adverse outcomes.
引用
- Scarsini R, Shanmuganathan M, De Maria GL, et al. Coronary Microvascular Dysfunction Assessed by Pressure Wire and CMR After STEMI Predicts Long-Term Outcomes. JACC Cardiovasc Imaging. 2021. PMID: 33865789. doi:10.1016/j.jcmg.2021.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。